公开(公告)号：US12234473B2

公开(公告)日：2025-02-25

申请号：US17563599

申请日：2021-12-28

Applicant: Immatics US, Inc.

Inventor： Gagan Bajwa ,  Mamta Kalra ,  Melinda Mata

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/86

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.

公开(公告)号：US20250019655A1

公开(公告)日：2025-01-16

申请号：US18893532

申请日：2024-09-23

Applicant: Immatics US, Inc.

Inventor： Amir ALPERT ,  Mamta KALRA

IPC: C12N5/0783 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N15/86

Abstract: A method for producing T cells with improved efficacy for adoptive immunotherapy includes obtaining a population of CD8+ T cells from a patient or a donor, determining a % of CD28+ CD8+ T cells in the obtained population, activating the determined population with anti-CD3 antibody and anti-CD28 antibody, provided that the determined population comprises at least 50% of CD28+ CD8+ T cells, or activating the determined population with anti-CD3 antibody in the absence of anti-CD28 antibody, provided that the determined population comprises less than 50% of CD28+ CD8+ T cells, transducing the activated population with a viral vector, and expanding the transduced population, in which the transducing and the expanding are carried out in the presence of at least one cytokine.

公开(公告)号：US12011459B2

公开(公告)日：2024-06-18

申请号：US16893246

申请日：2020-06-04

Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

Inventor： Amir Alpert ,  Dominik Maurer ,  Anastasiya Smith ,  Claudia Wagner ,  Ali Mohamed

IPC: A61K35/17 ,  A61K31/437 ,  A61K31/5383 ,  A61K35/76 ,  C07K14/47 ,  C07K14/725 ,  C12N5/0783 ,  G01N15/14 ,  G01N33/554 ,  G01N15/10 ,  G01N15/149

CPC classification number: A61K35/17 ,  A61K31/437 ,  A61K31/5383 ,  A61K35/76 ,  C07K14/47 ,  C07K14/7051 ,  C12N5/0636 ,  G01N15/1459 ,  G01N33/554 ,  C12N2501/2307 ,  C12N2501/50 ,  C12N2523/00 ,  G01N2015/1006 ,  G01N2015/1402 ,  G01N15/149 ,  G01N2333/705 ,  G01N2333/7051 ,  G01N2500/10

Abstract: Described herein are methods for preparing T cells, including isolating CD8+ T cells from a blood sample obtained from a patient or a donor, culturing the isolated CD8+ T cells in the presence of at least one cytokine, contacting the cultured CD8+ T cells with a multimer containing a target peptide in a complex with an MHC molecule and with at least one binding agent that binds to a T cell surface molecule, in which the multimer is labelled with a first detectable agent and the binding agent is labelled with a second detectable agent, sorting the contacted CD8+ T cells to collect the sorted CD8+ T cells that are detected positive for the first and the second detectable agents, and expanding the collected CD8+ T cells.

公开(公告)号：US20240115609A1

公开(公告)日：2024-04-11

申请号：US18319677

申请日：2023-05-18

Applicant: IMMATICS US, INC.

Inventor： Monique DAO ,  Steffen WALTER ,  Melinda MATA ,  Aleksandra NORWICKA ,  Yannick BULLIARD ,  Sarah MISSELL ,  Sabrina KUTTRUFF-COQUI ,  Norbert HILF

IPC: A61K35/17 ,  A61K31/663 ,  A61K31/675 ,  A61K38/20 ,  C07K14/54 ,  C07K14/55 ,  C12N5/00 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/85

CPC classification number: A61K35/17 ,  A61K31/663 ,  A61K31/675 ,  A61K38/2013 ,  C07K14/5443 ,  C07K14/55 ,  C12N5/0018 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/62 ,  C12N15/8509 ,  A61K2035/122 ,  C12N2501/155 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/515 ,  C12N2501/998 ,  C12N2740/10043

Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

公开(公告)号：US11905529B2

公开(公告)日：2024-02-20

申请号：US17062234

申请日：2020-10-02

Applicant: Immatics US, Inc.

Inventor： Amir Alpert

IPC: C12N5/0783 ,  A61P35/00 ,  A61K35/17

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61P35/00

Abstract: The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.

公开(公告)号：US20230142468A1

公开(公告)日：2023-05-11

申请号：US18053165

申请日：2022-11-07

Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

Inventor： Inbar ALFAGUTER ,  Sara YOUSEF ,  Kathy-Ann SECKER ,  Amir ALPERT ,  Juliane PALMER ,  Maike JAWORSKI

IPC: C12N5/00

CPC classification number: C12N5/0062 ,  C12N2533/90 ,  C12N2513/00

Abstract: The present disclosure relates to improved methods for generating multicellular spheroids. In embodiments, an improved method may comprise (a) providing cells capable of spheroid formation; (b) centrifuging the cells; (c) adding extracellular matrix to the cells of (b) to produce a cell suspension comprising a desired concentration of extracellular matrix; and (d) allowing at least one spheroid to form; wherein (b) is performed before (c). In embodiments, cells may be seeded on a tissue culture apparatus before extracellular matrix is added to the cells. In embodiments, spheroids may be characterized, analyzed, challenged, otherwise tested, or a combination thereof. In embodiments, cells may be seeded in a volume of media that is a fraction of a volume of media that is desired for characterization, analysis, challenging, otherwise testing, or a combination thereof.

公开(公告)号：US20230089392A1

公开(公告)日：2023-03-23

申请号：US17933418

申请日：2022-09-19

Applicant: Immatics US, Inc.

Inventor： Justin GUNESCH ,  Pooja MEHTA ,  Mamta KALRA

IPC: C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74

Abstract: A method for producing an engineered T cell population includes obtaining a cell population containing a monocyte and a T cell, resting the obtained cell population on a surface, adhering the monocyte to the surface, retaining a non-adherent cell population, activating the non-adherent cell population, introducing a nucleic acid into the activated non-adherent cell population to obtain a transformed T cell, and expanding the transformed T cell to obtain the engineered T cell population.

公开(公告)号：US20220056411A1

公开(公告)日：2022-02-24

申请号：US17409504

申请日：2021-08-23

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Gagan BAJWA ,  Thomas LUCAS ,  Ali MOHAMED ,  Steffen WALTER

IPC: C12N5/0783 ,  C12N15/85 ,  C07K14/725

Abstract: A method of producing an engineered T cell population includes obtaining a cell population comprising a CD8+ T cell, isolating the CD8+ T cell from the obtained cell population, activating the isolated CD8+ T cell, introducing a nucleic acid encoding a T cell receptor (TCR) binding to an antigen in a complex with an MHC molecule into the activated CD8+ T cell, and expanding the introduced CD8+ T cell to obtain the engineered T cell population.

公开(公告)号：US20210030803A1

公开(公告)日：2021-02-04

申请号：US17062331

申请日：2020-10-02

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Zoe Coughlin ,  Amir Alpert ,  Steffen Walter ,  Ali Mohamed ,  Agathe Bourgogne

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C12N15/86 ,  A61P31/00 ,  A61P35/00

Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.

公开(公告)号：US20210017493A1

公开(公告)日：2021-01-21

申请号：US17062234

申请日：2020-10-02

Applicant: Immatics US, Inc.

Inventor： Amir ALPERT

IPC: C12N5/0783 ,  A61P35/00 ,  A61K35/17

Abstract: The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.